Region-Specific Adipose Tissues And Liver Changes Associated With Semaglutide Treatment In Chronic Kidney Disease Patients
About the role
Actively Recruiting
Age: 18Years +
All Genders
ID07187830
Region-specific Adipose Tissues and Liver Changes Associated With Semaglutide Treatment in Chronic Kidney Disease Patients
Led by University of Alberta
Updated on 2026-05-11
52
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
Brief Title
Who Can Participate
AI-Screening
Your Study Journey
Trial Site Locations
How is the study designed?
Similar Trials
Frequently Asked Questions
Sponsors
U
University of Alberta
Lead Sponsor
N
Novo Nordisk Canada Inc.
Collaborating Sponsor
AI-Summary
What This Trial Is About
Obesity is a widespread health issue linked to several diseases and metabolic problems such as type 2 diabetes, high blood pressure, cholesterol issues, cancer, cardiovascular disease, and kidney disease. It affects kidney function both indirectly through diabetes and high blood pressure, and directly through harmful proteins called adipokines produced by fat cells. Researchers aim to better understand how these adipokines contribute to chronic inflammation and organ damage, particularly in the heart, liver, pancreas, and kidneys. This research focuses on studying a drug called semaglutide, a glucagon-like peptide-1 receptor agonist GLP-1Ra, which is known to help regulate blood sugar and promote weight loss while improving kidney and liver function. The study compares patients with type 2 diabetes and chronic kidney disease CKD who are either treated with semaglutide or not. Participants will undergo magnetic resonance imaging MRI scans to measure fat around the heart, liver, and kidneys, including liver fat content. Participants will first provide consent and then complete an MRI scan at the University of Albertas MRI Research Center. Researchers will collect information about medical history, medications, recent tests, and basic demographics such as age, sex, weight, and height. The study will track kidney disease progression and cardiometabolic changes over 12 months, alongside measuring biomarkers related to diseased fat tissue. The goal is to better understand how semaglutide impacts fat tissue and organ health in this population.
CONDITIONS
Brief Title
Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Patients aged 18 years or older Diagnosed with type 2 diabetes mellitus for more than 18 months Diagnosed with chronic kidney disease stages G1, G2, G3a, G3b, or G4 according to KDIGO guidelines Patients with or without semaglutide treatment Voluntarily agree to participate and sign informed consent
You will not qualify if you...
Patients younger than 18 years Pregnant, breastfeeding, or planning pregnancy without adequate contraception Diagnosed with chronic kidney disease stage G5 or stage G4 requiring dialysis Previous participation in this trial Diagnosed with neuropsychiatric diseases that prevent understanding of the study Known or suspected allergy to trial medications or related products Contraindications to study medications Refusal to participate or revocation of consent
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
On this page
AI-Summary
Brief Title
Who Can Participate
AI-Screening
Your Study Journey
Trial Site Locations
How is the study designed?
Similar Trials
Frequently Asked Questions
Sponsors
U
University of Alberta
Lead Sponsor
N
Novo Nordisk Canada Inc.
Collaborating Sponsor
About DecenTrialz
DecenTrialz is the trusted digital partner for the clinical research ecosystem, dedicated to accelerating medical innovation by fundamentally democratizing access to clinical trials. Our unified platform is engineered to dismantle the systemic geographical, socioeconomic, and informational barriers that have long hindered participation, seamlessly connecting sponsors, CROs, and sites with a more diverse and engaged population of participants. Grounded in an unwavering commitment to trust, ethical principles, and regulatory compliance, we empower researchers with the intelligent tools needed for efficient recruitment while providing patients with a clear, secure, and accessible pathway to participation. Ultimately, our work forges a more inclusive and effective research landscape, speeding the delivery of life-changing therapies to humanity.
Vision:
We envision a world where clinical research is a shared global effort, not limited by geography, income, or background. In this future, every community has a seat at the table of discovery, and trials reflect the true diversity of humanity. By broadening access and accelerating participation, we aim to transform how quickly innovation turns into care, creating a healthier future that belongs to everyone.
Goals:
Our Goal is to democratize clinical research by opening participation to people everywhere and ensuring diverse voices are represented in discovery. We work to remove barriers that slow progress, so research can move faster and bring new treatments to patients who need them. By making trials more inclusive and representative, we aim to strengthen trust in science and ensure that Medical breakthroughs serve humanity as a whole.
Similar Jobs
Region-Specific Adipose Tissues And Liver Changes Associated With Semaglutide Treatment In Chronic Kidney Disease Patients
About the role
Actively Recruiting
Age: 18Years +
All Genders
ID07187830
Region-specific Adipose Tissues and Liver Changes Associated With Semaglutide Treatment in Chronic Kidney Disease Patients
Led by University of Alberta
Updated on 2026-05-11
52
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
Brief Title
Who Can Participate
AI-Screening
Your Study Journey
Trial Site Locations
How is the study designed?
Similar Trials
Frequently Asked Questions
Sponsors
U
University of Alberta
Lead Sponsor
N
Novo Nordisk Canada Inc.
Collaborating Sponsor
AI-Summary
What This Trial Is About
Obesity is a widespread health issue linked to several diseases and metabolic problems such as type 2 diabetes, high blood pressure, cholesterol issues, cancer, cardiovascular disease, and kidney disease. It affects kidney function both indirectly through diabetes and high blood pressure, and directly through harmful proteins called adipokines produced by fat cells. Researchers aim to better understand how these adipokines contribute to chronic inflammation and organ damage, particularly in the heart, liver, pancreas, and kidneys. This research focuses on studying a drug called semaglutide, a glucagon-like peptide-1 receptor agonist GLP-1Ra, which is known to help regulate blood sugar and promote weight loss while improving kidney and liver function. The study compares patients with type 2 diabetes and chronic kidney disease CKD who are either treated with semaglutide or not. Participants will undergo magnetic resonance imaging MRI scans to measure fat around the heart, liver, and kidneys, including liver fat content. Participants will first provide consent and then complete an MRI scan at the University of Albertas MRI Research Center. Researchers will collect information about medical history, medications, recent tests, and basic demographics such as age, sex, weight, and height. The study will track kidney disease progression and cardiometabolic changes over 12 months, alongside measuring biomarkers related to diseased fat tissue. The goal is to better understand how semaglutide impacts fat tissue and organ health in this population.
CONDITIONS
Brief Title
Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Patients aged 18 years or older Diagnosed with type 2 diabetes mellitus for more than 18 months Diagnosed with chronic kidney disease stages G1, G2, G3a, G3b, or G4 according to KDIGO guidelines Patients with or without semaglutide treatment Voluntarily agree to participate and sign informed consent
You will not qualify if you...
Patients younger than 18 years Pregnant, breastfeeding, or planning pregnancy without adequate contraception Diagnosed with chronic kidney disease stage G5 or stage G4 requiring dialysis Previous participation in this trial Diagnosed with neuropsychiatric diseases that prevent understanding of the study Known or suspected allergy to trial medications or related products Contraindications to study medications Refusal to participate or revocation of consent
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
On this page
AI-Summary
Brief Title
Who Can Participate
AI-Screening
Your Study Journey
Trial Site Locations
How is the study designed?
Similar Trials
Frequently Asked Questions
Sponsors
U
University of Alberta
Lead Sponsor
N
Novo Nordisk Canada Inc.
Collaborating Sponsor
About DecenTrialz
DecenTrialz is the trusted digital partner for the clinical research ecosystem, dedicated to accelerating medical innovation by fundamentally democratizing access to clinical trials. Our unified platform is engineered to dismantle the systemic geographical, socioeconomic, and informational barriers that have long hindered participation, seamlessly connecting sponsors, CROs, and sites with a more diverse and engaged population of participants. Grounded in an unwavering commitment to trust, ethical principles, and regulatory compliance, we empower researchers with the intelligent tools needed for efficient recruitment while providing patients with a clear, secure, and accessible pathway to participation. Ultimately, our work forges a more inclusive and effective research landscape, speeding the delivery of life-changing therapies to humanity.
Vision:
We envision a world where clinical research is a shared global effort, not limited by geography, income, or background. In this future, every community has a seat at the table of discovery, and trials reflect the true diversity of humanity. By broadening access and accelerating participation, we aim to transform how quickly innovation turns into care, creating a healthier future that belongs to everyone.
Goals:
Our Goal is to democratize clinical research by opening participation to people everywhere and ensuring diverse voices are represented in discovery. We work to remove barriers that slow progress, so research can move faster and bring new treatments to patients who need them. By making trials more inclusive and representative, we aim to strengthen trust in science and ensure that Medical breakthroughs serve humanity as a whole.